泛癌中FXYD3预后和免疫浸润分析

Prognostic and Immune Infiltration Analysis of FXYD3 in Pan-Cancer

摘要: FXYD3作为一种跨膜蛋白，具有离子通道或离子通道调节的作用。目前已有相关研究提示FXYD3与某些肿瘤关系密切。在这项研究中，我们旨在探索FXYD3在泛癌中的作用，从加州大学圣克鲁兹西纳分校(UCSC)和癌症基因组图谱(TCGA)下载数据，分别对TCGA_GTEx、TCGA和TCGA配对样本中FXYD3的表达进行研究。随后，我们对TCGA数据库中肿瘤进行Kaplan-Meier分析，并对FXYD3影响预后的肿瘤进行临床相关性分析和单因素Cox回归分析。我们构建并评估膀胱尿路上皮癌(BLCA)、头颈鳞状细胞癌(HNSC)和肾透明细胞癌(KIRC)的列线图模型，以证明FXYD3在肿瘤中预测患者预后的价值。此外，我们证实FXYD3与免疫细胞浸润也有关系。通过功能富集分析，我们探索FXYD3相关基因参与的生物学功能及潜在信号通路。我们的研究发现FXYD3在多种肿瘤中存在差异表达，并与多种肿瘤的临床结局及免疫微环境相关，可能通过P53信号通路及免疫相关通路影响肿瘤的发生发展。总之，我们认为FXYD3可以作为潜在的预后生物标志物和有效的癌症免疫治疗靶点。

Abstract: FXYD3, as a transmembrane protein, has a role in ion channel or ion channel regulation. There have been studies suggesting that FXYD3 is closely related to certain tumors. In this study, we aimed to explore the role of FXYD3 in pan-cancer by downloading data from the University of California Santa Cruz (UCSC) Xena and The Cancer Genome Atlas (TCGA) to investigate the expression of FXYD3 in TCGA_GTEx, TCGA and TCGA paired samples, respectively. Subsequently, we performed Kaplan-Meier analyses of tumors in the TCGA database and performed clinical correlation and uni-variate Cox regression analyses of tumors in which FXYD3 affected prognosis. We constructed and evaluated nomogram models for bladder uroepithelial carcinoma (BLCA), head and neck squamous cell carcinoma (HNSC), and renal clear cell carcinoma (KIRC) to demonstrate the value of FXYD3 in tumors for predicting patient prognosis. In addition, we confirmed that FXYD3 was also associated with immune cell infiltration. Through functional enrichment analysis, we explored the biological functions and potential signaling pathways involved in FXYD3-related genes. Our study revealed that FXYD3 was differentially expressed in a variety of tumors and correlated with the clinical out-come and immune microenvironment of a variety of tumors, and may influence tumor development through the P53 signaling pathway and immune-related pathways. In conclusion, we believe that FXYD3 can be used as a potential prognostic biomarker and an effective target for cancer immuno-therapy.